Live Breaking News & Updates on Ffectiveness Immunogenicity

Stay updated with breaking news from Ffectiveness immunogenicity . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "We are pleased to offer a protein-based COVID-19 vaccine choice as a primary series to New Zealanders aged 12 and older and as a booster for adults 18 and older," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Providing Nuvaxovid now for adolescents may help increase vaccination rates amidst rising cases of COVID-19." The provisional approval was based on data from t ....

New Zealand , United States , New Zealanders , Zealand Medsafe , Giovanna Chandler , Erika Schultz , Stanleyc Erck , Biocelect Pty , World Health Organization , European Commission , Drug Administration , Prnewswire Novavax Inc , Exchange Commission , Administration Of Nuvaxovid , European Union , Serum Institute Of India , Novavax Inc , Chief Executive Officer , Safety Information , Product Characteristics , Package Leaflet , Prescribing Information , Important Safety Information , Serum Institute , Vaccine Efficacy Novavax Trial , New England Journal ,

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We are pleased to collaborate with SK b ....

South Korea , United States , Giovanna Chandler , Jaeyong Ahn , Erika Schultz , Stanleyc Erck , Korean Ministry Of Food , Drug Administration , Prnewswire Novavax Inc , Exchange Commission , Administration Of Nuvaxovid , European Union , Serum Institute Of India , Novavax Inc , Post Approval Change Application , Korean Ministry , Drug Safety , Chief Executive Officer , Name Use , Product Characteristics , Package Leaflet , Prescribing Information , Important Safety Information , Serum Institute , Vaccine Efficacy Novavax Trial , New England Journal ,

Novavax Nuvaxovid COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

Nuvaxovid COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17. The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 23, 2022. "With this authorization, we are extremely pleased to be able to offer our Nuvaxovid COVID-19 vaccine to adolescents in the EU," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Our protein-based vaccine was developed using an innovative approach to traditional technology ....

United States , Stanleyc Erck , Ali Chartan , Prnewswire Novavax , Department Of Defense , National Institute Of Allergy , European Union , Serum Institute Of India , Novavax Inc , National Institutes Of Health , Biomedical Advanced Research , Human Services , Us Department Of Health , Drug Administration , European Commission , World Health Organization , Development Authority , Exchange Commission , Administration Of Nuvaxovid , Office Of The , European Medicines Agency , Medicinal Products , Human Use , Chief Executive Officer , Serum Institute , New England Journal ,

Novavax COVID-19 Vaccine Nuvaxovid Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

Upon authorization, Nuvaxovid would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from the Phase 3 PREVENT-19 clinical trial. "This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Stanley C. Erck, President and Chie ....

United States , Stanleyc Erck , Ali Chartan , Department Of Defense , National Institute Of Allergy , European Union , Serum Institute Of India , Committee For Medicinal Products Human Use , Novavax Inc , National Institutes Of Health , Biomedical Advanced Research , Human Services , Us Department Of Health , World Health Organization , Drug Administration , European Commission , Development Authority , Exchange Commission , Administration Of Nuvaxovid , European Medicines Agency , Office Of The , Medicinal Products , Human Use , Chief Executive Officer , Serum Institute , New England Journal ,

Novavax COVID-19 Vaccine Nuvaxovid Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

Upon authorization, Nuvaxovid would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from the Phase 3 PREVENT-19 clinical trial. "This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Stanley C. Erck, President and Chie ....

United States , Stanleyc Erck , Ali Chartan , Department Of Defense , National Institute Of Allergy , European Union , Serum Institute Of India , Committee For Medicinal Products Human Use , Novavax Inc , National Institutes Of Health , Biomedical Advanced Research , Human Services , Us Department Of Health , World Health Organization , Drug Administration , European Commission , Development Authority , Exchange Commission , Administration Of Nuvaxovid , European Medicines Agency , Office Of The , Medicinal Products , Human Use , Chief Executive Officer , Serum Institute , New England Journal ,